Acurx Pharmaceuticals Announces Presentation of Ibezapolostat Phase 2 Clinical Trial Results at upcoming ESCMID 2024 Scientific Conference

Acurx Pharmaceuticals, Inc. ("Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today that results from the ibezapolstat Phase 2 clinical...

Related Keywords

United States ,Barcelona ,Comunidad Autonoma De Cataluna ,Spain ,Switzerland ,America ,Kevin Garey ,Eugenie Basseres ,Davidp Luci ,Acurx Pharmaceuticals Announces Presentation Of Ibezapolostat Phase ,Nasdaq ,University Of Houston College Pharmacy ,Exchange Commission ,Acurx Pharmaceuticals Inc ,Global European Society Of Clinical Microbiology ,Infectious Diseases Society Of America ,Prnewswire Acurx Pharmaceuticals Inc ,Data Monitoring Committee ,Research Scientist ,Trial Oversight Committee ,Exchange Commission On Form ,Acurx Pharmaceuticals ,Company Ph ,Society Or Healthcare Epidemiology Of America ,Drug Administration ,Company Scientific Advisory Board ,European Society Of Clinical Microbiology ,Pharmaceuticals Announces Presentation ,Ibezapolostat Phase ,Trial Results ,European Society ,Clinical Microbiology ,Infectious Diseases ,Houston College ,Principal Investigator ,Acurx Scientific Advisory Board ,Double Blind Study ,Ibezapolstat Compared ,Executive Committee ,Ibezapolstat Phase ,Scientific Advisory Board ,Clinical Cure ,Modified Intent ,Treat Population ,Per Protocol Population ,Prescribing Information ,Independent Data Monitoring Committee ,Fast Track Designated ,Gram Positive Selective Spectrum ,Qualified Infectious Disease Product ,Generating New Antibiotic Incentives Now ,Clinical Practice Guidelines ,Infectious Diseases Society ,Healthcare Epidemiology ,New England Journal ,Bile Acid ,Private Securities Litigation Reform Act ,